(VIANEWS) – Shares of DMS IMAGING (BEL 20: DMSIM.BR) dropped by a staggering 18.37% in 5 sessions from €0.02 to €0.02 at 02:12 EST on Wednesday, following the last session’s upward trend. BEL 20 is dropping 0.18% to €3,825.77, after two successive sessions in a row of gains.
About DMS IMAGING
DMS Imaging SA, a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen. The company is also developing hdm-ASIT+ for the treatment of house dust mite allergy; and pnt-ASIT+ for the treatment of peanut allergy. The company was formerly known as ASIT Biotech S.A. and changed its name to DMS Imaging SA in February 2022. DMS Imaging SA was incorporated in 1997 and is based in Liege, Belgium.
Earnings Per Share
As for profitability, DMS IMAGING has a trailing twelve months EPS of €0.19.
PE Ratio
DMS IMAGING has a trailing twelve months price to earnings ratio of 0.12. Meaning, the purchaser of the share is investing €0.12 for every euro of annual earnings.
Volume
Today’s last reported volume for DMS IMAGING is 122221 which is 88.3% below its average volume of 200283.
More news about DMS IMAGING (DMSIM.BR).
